DEA waiver and future impact on teleheatlh
Date postedOctober 19, 2022
At the start of the COVID-19 pandemic, the Drug Enforcement Agency waived the requirement for an in-person medical evaluation before prescribing of controlled substances as long as the prescription was for legitimate medical purposes, issued by a practitioner in the usual course of their professional practice, in accordance with federal and state laws, and prescribed following a real-time, two-way interactive telemedicine communication. This article explores what may happen to the waiver, and thus its impact on telehealth, when the public health emergency ends.